8.80
-0.09(-1.01%)
Currency In USD
| Previous Close | 8.89 |
| Open | 8.81 |
| Day High | 9.03 |
| Day Low | 8.75 |
| 52-Week High | 13.16 |
| 52-Week Low | 6.19 |
| Volume | 594,092 |
| Average Volume | 1.01M |
| Market Cap | 495.42M |
| PE | 18.72 |
| EPS | 0.47 |
| Moving Average 50 Days | 8.66 |
| Moving Average 200 Days | 9.35 |
| Change | -0.09 |
If you invested $1000 in Zevra Therapeutics, Inc. (ZVRA) 10 years ago, it would be worth $33.91 as of February 21, 2026 at a share price of $8.8. Whereas If you bought $1000 worth of Zevra Therapeutics, Inc. (ZVRA) shares 5 years ago, it would be worth $842.11 as of February 21, 2026 at a share price of $8.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™
GlobeNewswire Inc.
Feb 04, 2026 12:30 PM GMT
Real-world and clinical trial data underscore long-term safety and effectiveness in pediatric and adult NPC patientsCELEBRATION, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
GlobeNewswire Inc.
Feb 02, 2026 12:30 PM GMT
CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that it has been
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™
GlobeNewswire Inc.
Jan 26, 2026 12:30 PM GMT
Four abstracts highlighting clinical data and real-world experience with MIPLYFFA accepted for presentation, including an oral presentation by Caroline Hastings, MD Company to host satellite symposium on diagnostic and therapeutic advances in Niemann